Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer

Exclusion Criteria

• •Patients may not be receiving any other investigational agents
• •Patients should be excluded if they have had prior treatment with an anti-PD1 or anti-PD-L1. Please contact principal investigator, Benedito Carneiro, for specific questions on potential interactions
• •Patients with active autoimmune disease or history of autoimmune disease that might recur, which may affect vital organ function or require immune suppressive treatment including chronic prolonged systemic corticosteroids (defined as corticosteroid use of duration one month or greater), should be excluded; these include but are not limited to patients with a history of:
• •* Immune related neurologic disease
• •* Multiple sclerosis
• •* Autoimmune (demyelinating) neuropathy
• •* Guillain-Barre syndrome
• •* Myasthenia gravis
• •* Systemic autoimmune disease such as systemic lupus erythematosus (SLE)
• •* Connective tissue diseases
• •* Scleroderma
• •* Inflammatory bowel disease (IBD)
• •* Crohn's
• •* Ulcerative colitis
• •* Patients with a history of toxic epidermal necrolysis (TEN)
• •* Stevens-Johnson syndrome
• •* Anti-phospholipid syndrome; Note: subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll
• •Any condition requiring systemic treatment with corticosteroids (\> 10mg daily prednisone equivalents) or other immunosuppressive medications within 14 days prior to first dose of study drug; Note: inhaled steroids and adrenal replacement steroid doses \> 10mg daily prednisone equivalents are permitted in the absence of active autoimmune disease; a brief (less than 3 weeks) course of corticosteroids for prophylaxis (eg, contrast dye allergy) or for treatment of non-autoimmune conditions (eg, delayed-type hypersensitivity reaction caused by a contact allergen) is permitted
• •Hypertension that is not controlled on medication (Note: hypertension is defined as blood pressure \>= 140/90)
• •Ongoing or active infection requiring systemic treatment
• •Symptomatic congestive heart failure
• •Unstable angina pectoris
• •Cardiac arrhythmia
• •Psychiatric illness/social situations that would limit compliance with study requirements
• •Any other illness or condition that the treating investigator feels would interfere with study compliance or would compromise the patient's safety or study endpoints
• •No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for at least three years
• •Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) is not permitted
• •Any known positive test for hepatitis B or hepatitis C virus indicating acute or chronic infection is not permitted